These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12094213)

  • 1. Animal models of neurological deficits: how relevant is the rat?
    Cenci MA; Whishaw IQ; Schallert T
    Nat Rev Neurosci; 2002 Jul; 3(7):574-9. PubMed ID: 12094213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.
    Paillé V; Henry V; Lescaudron L; Brachet P; Damier P
    Mov Disord; 2007 Mar; 22(4):533-9. PubMed ID: 17230470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
    Pinna A; Wardas J; Simola N; Morelli M
    Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
    Jakowec MW; Petzinger GM
    Comp Med; 2004 Oct; 54(5):497-513. PubMed ID: 15575363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of motor disorders in animal models of Parkinson's disease].
    Campos-Romo A
    Rev Neurol; 2008 Feb 1-15; 46(3):167-74. PubMed ID: 18297625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine A2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease.
    Volpini R; Dal Ben D; Lambertucci C; Marucci G; Mishra RC; Ramadori AT; Klotz KN; Trincavelli ML; Martini C; Cristalli G
    ChemMedChem; 2009 Jun; 4(6):1010-9. PubMed ID: 19343763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options.
    Pitkänen A; Immonen RJ; Gröhn OH; Kharatishvili I
    Epilepsia; 2009 Feb; 50 Suppl 2():21-9. PubMed ID: 19187291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative T2 mapping as a potential marker for the initial assessment of the severity of damage after traumatic brain injury in rat.
    Kharatishvili I; Sierra A; Immonen RJ; Gröhn OH; Pitkänen A
    Exp Neurol; 2009 May; 217(1):154-64. PubMed ID: 19416663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Akinesia, motor oscillations and the pedunculopontine nucleus in rats and men.
    Stein JF
    Exp Neurol; 2009 Jan; 215(1):1-4. PubMed ID: 18977223
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute etomidate treatment reduces cognitive deficits and histopathology in rats with traumatic brain injury.
    Dixon CE; Ma X; Kline AE; Yan HQ; Ferimer H; Kochanek PM; Wisniewski SR; Jenkins LW; Marion DW
    Crit Care Med; 2003 Aug; 31(8):2222-7. PubMed ID: 12973183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buyang Huanwu Decoction can improve recovery of neurological function, reduce infarction volume, stimulate neural proliferation and modulate VEGF and Flk1 expressions in transient focal cerebral ischaemic rat brains.
    Cai G; Liu B; Liu W; Tan X; Rong J; Chen X; Tong L; Shen J
    J Ethnopharmacol; 2007 Sep; 113(2):292-9. PubMed ID: 17692486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
    Dupre KB; Eskow KL; Negron G; Bishop C
    Brain Res; 2007 Jul; 1158():135-43. PubMed ID: 17553470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal models of cognitive dysfunction.
    Tayebati SK
    Mech Ageing Dev; 2006 Feb; 127(2):100-8. PubMed ID: 16293295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model.
    Quik M; O'Neill M; Perez XA
    Trends Pharmacol Sci; 2007 May; 28(5):229-35. PubMed ID: 17412429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep brain stimulation in neurological diseases and experimental models: from molecule to complex behavior.
    Gubellini P; Salin P; Kerkerian-Le Goff L; Baunez C
    Prog Neurobiol; 2009 Sep; 89(1):79-123. PubMed ID: 19559747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys.
    Henderson JM; Stanic D; Tomas D; Patch J; Horne MK; Bourke D; Finkelstein DI
    Behav Brain Res; 2005 May; 160(2):267-76. PubMed ID: 15863223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marmoset monkey models of Parkinson's disease: which model, when and why?
    Eslamboli A
    Brain Res Bull; 2005 Dec; 68(3):140-9. PubMed ID: 16325013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.